Nkarta presents nkx019 clinical data at the european hematology association 2023 congress and 17th international conference on malignant lymphoma

South san francisco, calif., june 10, 2023 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies, today announced presentations highlighting preliminary data based on a november 2022 data cut-off from its phase 1 dose escalation clinical trial of nkx019 at two scientific conferences: the european hematology association (eha) 2023 hybrid congress and the 17th international conference on malignant lymphoma (17-icml). nkx019 is an allogeneic, off-the-shelf nk cell therapy candidate derived from healthy donors and engineered to target cd19.
NKTX Ratings Summary
NKTX Quant Ranking